Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2003-06-05
2009-10-06
Bertoglio, Valarie (Department: 1632)
Chemistry: molecular biology and microbiology
Vector, per se
C536S023200, C435S455000, C435S325000
Reexamination Certificate
active
07598077
ABSTRACT:
Artificial TERT promoters, which are useful for enhancing the differential expression of operably linked heterologous nucleic acid sequences, such as polypeptide cytotoxins, are disclosed herein. Methods for treating disease cells, such as cancer cells, while minimizing effects on normal, somatic cells by administering therapeutically effective amounts of heterologous nucleic acid sequences operably linked to artificial TERT promoters are provided. Kits containing artificial TERT promoters for enhancing differential expression are also provided.
REFERENCES:
patent: 5891639 (1999-04-01), Harley et al.
patent: 5972605 (1999-10-01), Villeponteau et al.
patent: 6054575 (2000-04-01), Villeponteau et al.
patent: 6258535 (2001-07-01), Villeponteau et al.
patent: 6261556 (2001-07-01), Weinrich et al.
patent: 6300110 (2001-10-01), Villeponteau et al.
patent: 6320039 (2001-11-01), Villeponteau et al.
patent: 6337200 (2002-01-01), Morin
patent: 6372742 (2002-04-01), Chin et al.
patent: 6391554 (2002-05-01), West et al.
patent: 6777203 (2004-08-01), Morin et al.
patent: 2002/0028785 (2002-03-01), Wold et al.
patent: 2005/0048466 (2005-03-01), Qian et al.
patent: WO/2003/006640 (2003-01-01), None
patent: WO 00/46355 (2000-08-01), None
patent: WO 02/42468 (2002-05-01), None
Li et al Nat Biotechnol. 1999;17(3):241-5.
Oskouian et al Biochem J, 1997, 324, 113-121.
Iyer and Struhl The EMBO Jornal vol. 14, 2570-2579, 1995.
Cong et al., “Histone deacetylation is involved in the transcriptional repression ofhTERTin normal human cells,”J. Biol. Chem. 275(46):35665-35668, Nov. 17, 2000.
Cong et al., “The human telomerase catalytic subunit hTERT: Organization of the gene and characterization of the promoter,”Hum. Mol. Gen. 8(1):137-142, 1999.
D'Costa et al., “Human immunodeficiency virus type 2 lentiviral vectors: packaging signal and splice donor in expression and encapsidation,”J. Gen. Virol. 82:425-434, 2001.
Farwell et al., “Genetic and epigenetic changes in human epithelial cells immortalized by telomerase,”Am. J. Virol.,156(5):1537-1547, May 2000.
Fujimoto et al., “Identification and characterization of negative regulatory elements of the human telomerase catalytic subunit (hTERT) gene promoter: possible role of MZF-2 in transcriptional repression of hTERT,”Nuc. Acids Res. 28(13):2557-2562, 2000.
Gu et al., “Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of theBaxgene to cancers,”Cancer Res. 60:5359-5364, Oct. 1, 2000.
Günes et al., “Expression ofhTERTgene is regulated at the level of transcriptional initiation and repressed by Mad1,”Cancer Res., 60:2116-2121, Apr. 15, 2000.
Horikawa et al., “Cloning and characterization of the promoter region ofhuman telomerase reverse transcriptasegene,”Cancer Res., 59:826-830, Feb. 15, 1999.
Horikawa et al., “Downstream E-box-mediated regulation of the human telomerase reverse transcriptase (hTERT) gene transcription: Evidence for an endogenous mechanism of transcriptional repression,”Mol. Biol. Cellpublished online Jun. 6, 2002, 10.1091/mbc.E01-11-0107.
Horikawa et al., “Multiple mechanisms in the transcriptional regulation of the human telomerase reverse transcriptase (hTERT) gene,”Am. Assoc. Cancer Res. 91stAnnual Meeting, Apr. 1-5, 2000. (abstract only).
Horikawa et al., “Transcriptional regulation of the telomerasehTERTgene as a target for cellular and viral oncogenic mechanisms,”Carcin. Adv. Acc. pp. 1-24, May 22, 2003.
Keith et al., “Telomerase-directed molecular therapeutics,”Exp. Rev. Mol. Med. pp. 1-22, Apr. 22, 2002.
Koch et al., “Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system,”Mol. Ther. 3(3):278-283, Mar. 2001. (abstract only).
Koga et al., “A novel telomerase-specific gene therapy: Gene transfer of Caspase-8 utilizing the human telomerase catalytic subunit gene promoter,”Hum. Gene Ther. 11:1397-1406, Jul. 1, 2000.
Komata et al., “Treatment of malignant glioma cells with the transfer of constitutively active Caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter,”Cancer Res., 61:5796-5802, Aug. 1, 2001.
Kyo et al., “Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT),”Nuc. Acids Res. 28(3): 669-677, 2000.
Lee et al., “Human Papillomavirus E2 Down-regulates the Human Telomerase Reverse Transcriptase Promoter,”J. Biol. Chem. 277(31):27748-27756, Aug. 2, 2002.
Leem et al., “The human telomerase gene: complete genomic sequence and analysis of tandem repeat polymorphisms in intronic regions,”Oncogene21(5):769-77, Jan. 24, 2002. (abstract only).
Lin et al., “Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes,”Cancer Res. 62:3620-3625, Jul. 1, 2002.
Majumdar et al., “The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters,”Gene Ther. 8:568-578, 2001.
Misiti et al., “Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells,”Mol. Cell Biol. 20(11):3764-3771, Jun. 2000.
Nettelbeck et al., “Gene therapy designer promoters for tumour targeting,”TIG, 16(4):174-181, Apr. 2000.
Nielsen et al., “Murine helix-loop-helix transcriptional activator proteins binding to the E-box motif of the Akv murine leukemia virus enhancer identified by cDNA cloning,”Mol. Cell Biol. 12(8):3449-59, Aug. 1992. (abstract only).
Nyanguile et al., “A nonnatural transcriptional coactivator,”Proc. Natl. Acad. Sci. USA94:13402-13406, Dec. 1997.
Oh et al., “In vivo and in vitro analyses of Myc for differential promoter activities of the human telomerase (hTERT) gene in normal and tumor cells,”Biochem. Biophys. Res. Comm. 263:361-365, 1999.
Oh et al., “The Wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene,”J. Biol. Chem. 274(52):37473-37478, Dec. 24, 1999.
Pollock et al., “Transcriptional activation: Is it rocket science?”Proc. Natl. Acad. Sci. USA94:13388-13389, Dec. 1997.
Prowse et al., “Developmental and tissue-specific regulation of mouse telomerase and telomere length,”Proc. Natl. Acad. Sci. USA92:4818-4822, May 1995.
Reddel, “The role of senescence and immortalization in carcinogenesis,”Carcinogen. 21(3):477-484, 2000.
Takakura et al., “Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells,”Cancer Res. 59:551-557, Feb. 1, 1999.
Wirth et al., “A Telomerase-dependent Conditionally Replicating Adenovirus for Selective Treatment of Cancer,”Cancer Res. 63:3181-3188, Jun. 15, 2003.
Barrett J. Carl
Horikawa Izumi
Bertoglio Valarie
Klarquist & Sparkman, LLP
Singh Anoop
The United States of America as represented by the Department of
LandOfFree
Compositions and methods for enhancing differential expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for enhancing differential expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for enhancing differential expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4099950